U.S. FDA grants Rare Paediatric Disease Designation to silmitasertib for treatment of recurrent sonic hedgehog medulloblastoma

Silmitasertib is a Casein Kinase 2 inhibitor, being developed as treatment for this brain tumor in children, the usual treatment of which involves surgery, followed by radiation or chemotherapy, or both. Phase I/II study has shown disease stabilisation.


Biospace Inc.